FGFR4 and hepatocellular carcinoma: For HCC patients with high FGFR4 expression, 84.52% had mutations, with the first three mutations being Tumor Protein P53 (TP53) (35%), Catenin Beta 1 (CTNNB1) (21%), and Titin (TTN) (18%) (Supplementary Figure S3B), suggesting the predictive value of FGFR4 as a biomarker in HCC.